Spectrum Pharmaceuticals Announces the USPTO Has Granted Five-Year Extension for FOLOTYN(R) Patent
FOLOTYN® (pralatrexate injection) is the first therapeutic to have been approved for peripheral T-cell lymphoma (PTCL), in September 2009
FOLOTYN net sales were approximately $50 million in 2011
Spectrum acquired FOLOTYN through acquisition of Allos Therapeutics on September 5, 2012
http://www.cnbc.com/id/49326747
FOLOTYN® (pralatrexate injection) is the first therapeutic to have been approved for peripheral T-cell lymphoma (PTCL), in September 2009
FOLOTYN net sales were approximately $50 million in 2011
Spectrum acquired FOLOTYN through acquisition of Allos Therapeutics on September 5, 2012
http://www.cnbc.com/id/49326747
